JP2013503344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503344A5 JP2013503344A5 JP2012527009A JP2012527009A JP2013503344A5 JP 2013503344 A5 JP2013503344 A5 JP 2013503344A5 JP 2012527009 A JP2012527009 A JP 2012527009A JP 2012527009 A JP2012527009 A JP 2012527009A JP 2013503344 A5 JP2013503344 A5 JP 2013503344A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- progression
- threshold
- rifle stage
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036470 plasma concentration Effects 0.000 claims 14
- 210000002700 urine Anatomy 0.000 claims 14
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 11
- 208000033626 Renal failure acute Diseases 0.000 claims 11
- 201000011040 acute kidney failure Diseases 0.000 claims 11
- 208000012998 acute renal failure Diseases 0.000 claims 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 210000003734 kidney Anatomy 0.000 claims 7
- 238000003556 assay Methods 0.000 claims 6
- 230000003247 decreasing effect Effects 0.000 claims 6
- 229940109239 creatinine Drugs 0.000 claims 5
- 230000003907 kidney function Effects 0.000 claims 5
- 238000012959 renal replacement therapy Methods 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 102100030856 Myoglobin Human genes 0.000 claims 4
- 108010062374 Myoglobin Proteins 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 4
- 239000010839 body fluid Substances 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 230000002250 progressing effect Effects 0.000 claims 4
- 102100030942 Apolipoprotein A-II Human genes 0.000 claims 3
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 3
- 108010008629 CA-125 Antigen Proteins 0.000 claims 3
- 102000000905 Cadherin Human genes 0.000 claims 3
- 108050007957 Cadherin Proteins 0.000 claims 3
- 102100024151 Cadherin-16 Human genes 0.000 claims 3
- 101710196874 Cadherin-16 Proteins 0.000 claims 3
- 102100029761 Cadherin-5 Human genes 0.000 claims 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 3
- 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 3
- 102100035904 Caspase-1 Human genes 0.000 claims 3
- 108090000426 Caspase-1 Proteins 0.000 claims 3
- 108090000566 Caspase-9 Proteins 0.000 claims 3
- 102000004039 Caspase-9 Human genes 0.000 claims 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims 3
- 101710157567 Cyclin-dependent kinase inhibitor 1 Proteins 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 102100023123 Mucin-16 Human genes 0.000 claims 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 3
- 101710178278 Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 3
- 108010018828 cadherin 5 Proteins 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 238000013517 stratification Methods 0.000 claims 3
- 102100027453 Bcl2-associated agonist of cell death Human genes 0.000 claims 2
- 101710081085 Bcl2-associated agonist of cell death Proteins 0.000 claims 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23811809P | 2009-08-28 | 2009-08-28 | |
| US23812109P | 2009-08-28 | 2009-08-28 | |
| US23812009P | 2009-08-28 | 2009-08-28 | |
| US23812509P | 2009-08-28 | 2009-08-28 | |
| US23812909P | 2009-08-28 | 2009-08-28 | |
| US23812809P | 2009-08-28 | 2009-08-28 | |
| US23813409P | 2009-08-28 | 2009-08-28 | |
| US23812709P | 2009-08-28 | 2009-08-28 | |
| US23812309P | 2009-08-28 | 2009-08-28 | |
| US23811509P | 2009-08-28 | 2009-08-28 | |
| US61/238,134 | 2009-08-28 | ||
| US61/238,123 | 2009-08-28 | ||
| US61/238,128 | 2009-08-28 | ||
| US61/238,120 | 2009-08-28 | ||
| US61/238,127 | 2009-08-28 | ||
| US61/238,115 | 2009-08-28 | ||
| US61/238,118 | 2009-08-28 | ||
| US61/238,125 | 2009-08-28 | ||
| US61/238,129 | 2009-08-28 | ||
| US61/238,121 | 2009-08-28 | ||
| US24400209P | 2009-09-18 | 2009-09-18 | |
| US24399309P | 2009-09-18 | 2009-09-18 | |
| US24399709P | 2009-09-18 | 2009-09-18 | |
| US24399109P | 2009-09-18 | 2009-09-18 | |
| US61/243,997 | 2009-09-18 | ||
| US61/243,993 | 2009-09-18 | ||
| US61/243,991 | 2009-09-18 | ||
| US61/244,002 | 2009-09-18 | ||
| PCT/US2010/046910 WO2011025917A1 (en) | 2009-08-28 | 2010-08-27 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015135079A Division JP6054481B2 (ja) | 2009-08-28 | 2015-07-06 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503344A JP2013503344A (ja) | 2013-01-31 |
| JP2013503344A5 true JP2013503344A5 (enExample) | 2013-10-17 |
| JP5775874B2 JP5775874B2 (ja) | 2015-09-09 |
Family
ID=43628398
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527009A Expired - Fee Related JP5775874B2 (ja) | 2009-08-28 | 2010-08-27 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP2015135079A Expired - Fee Related JP6054481B2 (ja) | 2009-08-28 | 2015-07-06 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015135079A Expired - Fee Related JP6054481B2 (ja) | 2009-08-28 | 2015-07-06 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120315649A1 (enExample) |
| EP (3) | EP2470905B1 (enExample) |
| JP (2) | JP5775874B2 (enExample) |
| CN (2) | CN102792161B (enExample) |
| AU (1) | AU2010286559B2 (enExample) |
| CA (1) | CA2772336A1 (enExample) |
| HK (1) | HK1208074A1 (enExample) |
| NZ (2) | NZ598712A (enExample) |
| WO (1) | WO2011025917A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| DK2666872T3 (en) * | 2010-02-05 | 2016-07-25 | Astute Medical Inc | Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency |
| US20130203074A1 (en) | 2010-06-23 | 2013-08-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN103080743B (zh) * | 2010-06-23 | 2015-07-22 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| US10557856B2 (en) | 2010-09-24 | 2020-02-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biomarkers of renal injury |
| US9551720B2 (en) | 2011-01-26 | 2017-01-24 | University of Pittsburgh—Of the Commonwaelth System of Higher Education | Urine biomarkers for prediction of recovery after acute kidney injury: proteomics |
| EP2503340A1 (en) * | 2011-03-22 | 2012-09-26 | Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada | Diagnostic marker for relapsing primary idiopathic focal segmental glomerulosclerosis |
| TW201250248A (en) * | 2011-04-25 | 2012-12-16 | Kyowa Medex Co Ltd | Prognostication method of renal failure |
| WO2012155123A2 (en) * | 2011-05-12 | 2012-11-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2013086359A1 (en) | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20150293131A1 (en) * | 2012-04-02 | 2015-10-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of sepsis |
| CA3158996C (en) * | 2013-01-17 | 2024-06-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN104569417B (zh) * | 2013-10-12 | 2016-06-01 | 广州瑞博奥生物科技有限公司 | 一种用于早期诊断急性肾损伤的抗体芯片试剂盒 |
| CN105917229B (zh) | 2013-12-03 | 2019-04-26 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| WO2016164854A1 (en) | 2015-04-09 | 2016-10-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN107735147A (zh) * | 2015-05-12 | 2018-02-23 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| AU2017277305A1 (en) | 2016-06-06 | 2018-12-20 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| CN112384807A (zh) | 2018-05-24 | 2021-02-19 | 雷尼布斯治疗公司 | 治疗有风险患有肾损伤和肾衰竭的患者的方法 |
| CN117825674A (zh) * | 2023-12-28 | 2024-04-05 | 南方医科大学南方医院 | 用于评估肝病预后的分子标志物及诊断试剂盒 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| ATE177841T1 (de) | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| AU1674400A (en) * | 1998-12-21 | 2000-07-12 | Monash University | Kidney disease detection and treatment |
| WO2002048329A2 (en) * | 2000-11-20 | 2002-06-20 | Idun Pharmaceuticals, Inc. | Membrane derived caspase-3, compositions comprising the same and methods of use therefor |
| WO2002081515A1 (fr) * | 2001-04-03 | 2002-10-17 | Kyowa Hakko Kogyo Co., Ltd. | Proteine de liaison de facteur de croissance de type insuline |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
| EP2360475B1 (en) * | 2003-03-27 | 2019-10-02 | Children's Hospital Medical Center | A method and kit for detecting the early onset of renal tubular cell injury |
| CN1791797A (zh) * | 2003-03-27 | 2006-06-21 | 儿童医院医疗中心 | 用于检测肾小管细胞损伤的早发的方法和试剂盒 |
| US7416854B2 (en) * | 2004-01-22 | 2008-08-26 | Promega Corporation | Luminogenic and nonluminogenic multiplex assay |
| US20090215046A1 (en) * | 2004-01-27 | 2009-08-27 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays methods of use thereof for diagnosis of colon cancer |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| US7141382B1 (en) * | 2004-10-12 | 2006-11-28 | Parikh Chirag R | Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality |
| CN101163971B (zh) * | 2004-12-20 | 2013-03-20 | 免疫体公司 | 测定作为肾病诊断标记物的嗜中性粒细胞明胶酶相关性脂笼蛋白 |
| WO2006102979A2 (de) * | 2005-03-31 | 2006-10-05 | Johannes Gutenberg-Universität Mainz | Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen |
| EP1880332A4 (en) * | 2005-04-27 | 2010-02-17 | Emiliem | NOVEL METHODS AND DEVICES FOR EVALUATING TOXIC SUBSTANCES |
| TW200716764A (en) * | 2005-05-02 | 2007-05-01 | Genenews Inc | Bladder cancer biomarkers and uses thereof |
| WO2006133399A1 (en) * | 2005-06-08 | 2006-12-14 | Hitachi Chemical Research Center, Inc. | METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES |
| US7662578B2 (en) * | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
| US8129135B2 (en) * | 2006-04-24 | 2012-03-06 | Medizinische Universität Wien | Method for diagnosing cardiovascular diseases |
| PL2115477T3 (pl) * | 2007-01-25 | 2015-12-31 | Hoffmann La Roche | Zastosowanie IGFBP-7 do oceny niewydolności serca |
| EP2134866A2 (en) * | 2007-04-10 | 2009-12-23 | Integragen | Human diabetes susceptibility tnfrsf10b gene |
| US20110183434A1 (en) * | 2008-01-17 | 2011-07-28 | Myles Wolf | Diagnostic methods and kits using fibroblast growth factor-23 |
| CN104020284B (zh) * | 2008-10-21 | 2016-08-24 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
-
2010
- 2010-08-27 CN CN201080045575.5A patent/CN102792161B/zh not_active Expired - Fee Related
- 2010-08-27 EP EP10812639.2A patent/EP2470905B1/en not_active Not-in-force
- 2010-08-27 JP JP2012527009A patent/JP5775874B2/ja not_active Expired - Fee Related
- 2010-08-27 WO PCT/US2010/046910 patent/WO2011025917A1/en not_active Ceased
- 2010-08-27 CA CA2772336A patent/CA2772336A1/en not_active Abandoned
- 2010-08-27 NZ NZ598712A patent/NZ598712A/en not_active IP Right Cessation
- 2010-08-27 US US13/393,075 patent/US20120315649A1/en not_active Abandoned
- 2010-08-27 AU AU2010286559A patent/AU2010286559B2/en not_active Ceased
- 2010-08-27 NZ NZ624609A patent/NZ624609A/en not_active IP Right Cessation
- 2010-08-27 EP EP16189562.8A patent/EP3151005A1/en not_active Withdrawn
- 2010-08-27 EP EP15150059.2A patent/EP2894473B1/en not_active Not-in-force
- 2010-08-27 CN CN201410573713.7A patent/CN104483488A/zh active Pending
-
2015
- 2015-03-31 US US14/675,344 patent/US20150204892A1/en not_active Abandoned
- 2015-07-06 JP JP2015135079A patent/JP6054481B2/ja not_active Expired - Fee Related
- 2015-09-04 HK HK15108654.3A patent/HK1208074A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503344A5 (enExample) | ||
| JP2013519095A5 (enExample) | ||
| JP2014529073A5 (enExample) | ||
| JP2013501920A5 (enExample) | ||
| JP2012517594A5 (enExample) | ||
| JP2013531240A5 (enExample) | ||
| JP2013539861A5 (enExample) | ||
| JP2013510321A5 (enExample) | ||
| JP2012517592A5 (enExample) | ||
| HRP20160733T1 (hr) | Postupci i pripravci za postavljanje dijagnoze i prognoze ozljede bubrega i bubrežne insuficijencije | |
| Ronco et al. | Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative | |
| JP2015129764A5 (enExample) | ||
| EP2479568B1 (en) | Predictive renal safety biomarkers and biomarker signatures to monitor kidney function | |
| JP2021039112A5 (enExample) | ||
| JP2013510322A5 (enExample) | ||
| JP2013513086A5 (enExample) | ||
| Ostermann et al. | Clinical review: Biomarkers of acute kidney injury: where are we now? | |
| US9551720B2 (en) | Urine biomarkers for prediction of recovery after acute kidney injury: proteomics | |
| ES2821383T3 (es) | Firmas genéticas de trastornos inflamatorios relacionados con el hígado y la enfermedad de Crohn | |
| Caragata et al. | Acute kidney injury following liver transplantation: a systematic review of published predictive models | |
| US20200271669A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| Liu et al. | Blood urea nitrogen in the prediction of in-hospital mortality of patients with acute aortic dissection | |
| TR201807542T4 (tr) | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. | |
| Koyner et al. | Adjudication of etiology of acute kidney injury: experience from the TRIBE-AKI multi-center study | |
| JP2013519866A5 (enExample) |